Black checkmark with a sparkle and a curved line underneath on a white background.
Company

GridAI Technologies Corp.

Ticker
GRDX
Sector
Industry
Report date
November 17, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include leadership changes, financing activities, a proposed reverse merger, and a corporate name change reflecting strategic repositioning.

Recent developments:
  • Entero Therapeutics appointed Richard Paolone as interim CEO in February 2025 [N3].
  • The company secured a $2 million loan and appointed new board members in February 2025 [N4].
  • Announced a proposed reverse merger with Journey Therapeutics in November 2024 [N5].
  • Stock gained 5% ahead of the name change to GridAI in November 2025 [N2].
  • Biotech sector momentum including GridAI was noted in after-hours trading in December 2025 [N1].
Overview

GridAI Technologies Corp. is a biotechnology company that has recently undergone significant corporate changes including a proposed reverse merger with Journey Therapeutics and a rebranding from Entero Therapeutics to GridAI. The company operates in the biotech sector with a focus on commercializing its technologies. Recent leadership changes include the appointment of an interim CEO in early 2025. Financial disclosures indicate ongoing net losses and liquidity constraints, with a low current ratio and cash ratio as of the latest quarter. The company has faced delays in commercialization and customer contract execution, which have materially affected its financial performance.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. GridAI Technologies Corp., formerly Entero Therapeutics, has undergone leadership changes, secured financing, and announced a reverse merger and name change. The company reported a net loss for 2025 and faces liquidity challenges with a current ratio of 0.26 as of September 30, 2026. Delays in commercialization and customer contract execution have impacted operating results and led to a goodwill impairment charge [S1][S2][N3][N4][N5][N2].

Scenarios for GRDX

Bull case model:

GridAI has taken strategic steps including a reverse merger and leadership restructuring to reposition itself in the biotech market. The company has secured financing and is working on commercializing its technologies. Positive momentum in the biotech sector and recent corporate developments may support improved execution and customer adoption. The company's intellectual property and technology rights provide a foundation for potential growth in its niche.

Bear case model:

The company faces significant risks including delays in commercialization and customer contract execution, which have already resulted in a goodwill impairment charge. Liquidity ratios indicate financial strain with a current ratio well below 1 and minimal cash reserves. Continued net losses and dependence on successful execution of commercial agreements pose challenges. The biotech sector's competitive and regulatory environment adds further uncertainty to the company's prospects.

Moat:

GridAI's moat appears to be linked to its proprietary technologies and strategic transactions such as the reverse merger with Journey Therapeutics. The company holds developed technology rights, patents, and customer relationships as indicated in SEC filings. However, the company faces challenges in commercialization and customer adoption, which are critical to establishing a sustainable competitive advantage. The biotech sector's inherent risks and the company's liquidity constraints also impact its moat strength.

Risks overview
Risks summary
The most significant risks for GridAI Technologies Corp. relate to execution delays in commercialization, liquidity constraints, and dependence on capital access, all of which could materially affect its business and financial condition.
Risks details:

• Commercialization and Execution Risks: Delays in commercialization and customer contract execution have negatively impacted operating results and contributed to a goodwill impairment charge of approximately $10.1 million during Q2 2026 [S2].
• Liquidity and Financial Risks: As of September 30, 2026, the company has a current ratio of 0.26 and a cash ratio of 0.02, indicating potential liquidity challenges [S2].
• Dependence on Capital Access: The company's ability to achieve results depends on access to sufficient capital to fund operations and commercialization efforts [S2].
• Leadership and Strategic Risks: Recent leadership changes including appointment of an interim CEO may impact strategic direction and execution [N3].
• Industry and Regulatory Risks: Operating in the biotech sector involves regulatory uncertainties and competitive pressures that may affect the company's business model and financial condition.

FINAL FORECAST FOR GRDX

Final take one line
GridAI Technologies Corp. exhibits very high visibility with detailed SEC disclosures and recent news covering leadership, financing, and strategic corporate changes.
Final take 12 to 24 month view

Business trends: The company is navigating a transition with a reverse merger, leadership changes, and efforts to commercialize biotech technologies amid sector momentum.
Execution milestones: Key milestones include securing financing, appointing new leadership, and completing a corporate rebranding.
Key risks: Execution delays, liquidity constraints, dependence on capital access, and biotech industry uncertainties remain significant risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • GridAI Technologies Corp. is the current name of the company formerly known as Entero Therapeutics, Inc.
  • The company announced a proposed reverse merger with Journey Therapeutics in November 2024 [N5].
  • In early 2025, Entero Therapeutics secured a $2 million loan and appointed new board members [N4].
  • Richard Paolone was appointed as interim CEO in February 2025 [N3].
  • The company announced a name change to GridAI in late November 2025 [N2].
  • Recent news indicates some positive momentum in the biotech sector including GridAI [N1].
  • As of September 30, 2026, the company reported cash and cash equivalents of $239,834 and current assets of approximately $3.9 million, with current liabilities of about $14.9 million, resulting in a current ratio of 0.26 and a cash ratio of 0.02 [S2].
  • The company reported a net loss of approximately $6.55 million for the year ended December 31, 2025 [S1].
  • Basic and diluted earnings per share were both negative $0.27 as of September 30, 2026 [S2].
  • The company has experienced delays in commercialization and customer contract execution, which contributed to a goodwill impairment charge of approximately $10.1 million during Q2 2026 [S2].
  • Risk factors include dependence on timely execution of commercial agreements, successful commercialization and deployment of technologies, customer adoption, and access to sufficient capital [S2].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-05-01 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2025-12-01 | www.nasdaq.com | Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb | https://www.nasdaq.com/articles/biotech-momentum-builds-after-hours-trading-bioatla-entero-and-sonnet-climb
  • N2 | 2025-11-28 | www.nasdaq.com | Entero Therapeutics Stock Gains 5% Ahead Of Name Change To GridAI | https://www.nasdaq.com/articles/entero-therapeutics-stock-gains-5-ahead-name-change-gridai
  • N3 | 2025-02-14 | www.nasdaq.com | Entero Therapeutics, Inc. Appoints Richard Paolone as Interim CEO | https://www.nasdaq.com/articles/entero-therapeutics-inc-appoints-richard-paolone-interim-ceo
  • N4 | 2025-02-07 | www.nasdaq.com | Entero Therapeutics Secures $2 Million Loan and Appoints New Board Members | https://www.nasdaq.com/articles/entero-therapeutics-secures-2-million-loan-and-appoints-new-board-members
  • N5 | 2024-11-13 | www.nasdaq.com | Entero Therapeutics announces proposed reverse merger with Journey Therapeutics | https://www.nasdaq.com/articles/entero-therapeutics-announces-proposed-reverse-merger-journey-therapeutics
  • N6 | 2024-08-11 | www.nasdaq.com | Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray | https://www.nasdaq.com/articles/weekly-review-antx-downsizes-aldx-aces-dry-eye-disease-trial-fda-oks-1st-epinephrine-nasal
  • N7 | 2024-04-05 | www.nasdaq.com | Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now | https://www.nasdaq.com/articles/heres-why-first-wave-biopharma-fwbi-is-a-great-buy-the-bottom-stock-now
  • N8 | 2024-03-04 | www.nasdaq.com | First Wave BioPharma Prices Direct Offering Of 525,625 Shares; Stock Slips 22% In Pre-market | https://www.nasdaq.com/articles/first-wave-biopharma-prices-direct-offering-of-525625-shares-stock-slips-22-in-pre-market
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine